Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Hoth Therapeutics licenses UMB's RAMBAs to develop dermatology therapeutics

Executive Summary

Hoth Therapeutics Inc. gets exclusive rights within dermatology to develop and commercialize retinoic acid metabolism blocking agents (RAMBAs) from the University of Maryland, Baltimore (UMB) and its spin-out company Isoprene Pharmaceuticals Inc.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register